Generation Bio (NASDAQ:GBIO) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Generation Bio (NASDAQ:GBIO) released its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.01), Zacks reports. Generation Bio had a negative net margin of 782.86% and a negative return on equity of 104.85%.

Generation Bio Stock Down 2.5 %

Shares of NASDAQ:GBIO traded down $0.01 during midday trading on Thursday, hitting $0.51. The stock had a trading volume of 271,037 shares, compared to its average volume of 518,725. The company has a market cap of $34.20 million, a P/E ratio of -0.23 and a beta of 2.72. The business’s 50-day simple moving average is $0.77 and its 200-day simple moving average is $1.55. Generation Bio has a 12 month low of $0.47 and a 12 month high of $4.65.

Analysts Set New Price Targets

Separately, Needham & Company LLC dropped their target price on Generation Bio from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th.

Insider Activity

In related news, Director Anthony G. Quinn purchased 125,791 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were acquired at an average price of $0.96 per share, for a total transaction of $120,759.36. Following the purchase, the director now owns 214,286 shares in the company, valued at approximately $205,714.56. This represents a 142.14 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 21.10% of the stock is owned by insiders.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.